Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study

期刊论文
出版模式：

开放获取
发表日期：

2024年7月5日

查看全文

Neal Shore,
Jason Hafron,
Daniel Saltzstein,
Amitabha Bhaumik,
Pankaj Aggarwal,
Jennifer Phillips,
Tracy McGowan

摘要

Background/objectives

Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.

Subjects/methods

A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.

Results

Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.

Conclusions

Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.